Adding pharmacists to primary care teams increases guideline-concordant antiplatelet use in patients with type 2 diabetes: Results from a randomized trial

Annals of Pharmacotherapy

Volumn 47, Issue 1, 2013, Pages 43-48

  Gilani, Fizza ^a   Majumdar, Sumit R ^a   Johnson, Jeffrey A ^a   Tsuyuki, Ross T ^a   Lewanczuk, Richard Z ^a   Spooner, Richard ^a   Simpson, Scot H ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACIST; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SECONDARY PREVENTION; SYSTOLIC BLOOD PRESSURE;

AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; PATIENT CARE TEAM; PHARMACEUTICAL SERVICES; PHARMACISTS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PROFESSIONAL ROLE; TIME FACTORS;

EID: 84872929542     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R552     Document Type: Article

References (32)

1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(suppl 2):S14-S21.
2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardio-vascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36.
3. Jansson SP, Andersson DK, Svardsudd K. Mortality trends in subjects with and without diabetes during 33 years of follow-up. Diabetes Care 2010;33:551-556.
4. Tan MH, MacLean DR. Epidemiology of diabetes melli-tus in Canada. Clin Invest Med 1995;18:240-246.
5. Nathan DM, Meigs J, Singer DE. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is...or is it? Lancet 1997; 350(suppl 1):S14-S19.
6. Gaede P, Vedel P, Larsen N, Jensen G V, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.
7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358:580-591.
8. Canadian Diabetes Association Clinical Practice Guide- lines Expert Committee. Macrovascular complications, dyslipidemia and hypertension. Can J Diabetes 2003;27:S58-S65.
9. Canadian Diabetes Association Clinical Practice Guide-lines Expert Committee. Vascular protection in people with diabetes. Can J Diabetes 2008;32:S102-S106.
10. Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia 2008;51:385-390.
11. Cerbone AM, Macarone-Palmieri N, Saldalamacchia G, Coppola A, Di Minno G, Rivellese AA. Diabetes, vascular complications and antiplatelet therapy: open prob- lems. Acta Diabetol 2009;46:253-261.
12. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136.
13. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes. Diabetes Care 2010;33:1395-1402.
14. Law EH, Simpson SH. Aspirin use rates in diabetes: a systematic review and cross-sectional study. Can J Diabetes 2010;34:211-217.
15. Isetts BJ, Brown LM, Schondelmeyer SW, Lenarz LA. Quality assessment of a collaborative approach for decreasing drug-related morbidity and achieving therapeutic goals. Arch Intern Med 2003;163:1813-1820.
16. Altavela JL, Jones MK, Ritter M. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. J Manag Care Pharm 2008;14:831-843.
17. Isetts BJ, Schondelmeyer SW, Artz MB, et al. Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc 2008;48:203-211.
18. Monte SV, Slazak EM, Albanese NP, Adelman M, Rao G, Paladino JA. Clinical and economic impact of a diabetes clinical pharmacy service program in a university and primary care-based collaboration model. J Am Pharm Assoc 2009;49:200-208.
19. Westerlund T, Marklund B. Assessment of the clinical and economic out- comes of pharmacy interventions in drug-related problems. J Clin Pharm Ther 2009;34:319-327.
20. MacLaren R, Bond CA. Effects of pharmacist participation in intensive care units on clinical and economic outcomes of critically ill patients with throm-boembolic or infarction-related events. Pharmacotherapy 2009;29:761-768.
21. Horning KK, Hoehns JD, Doucette WR. Adherence to clinical practice guidelines for 7 chronic conditions in long-term-care patients who received pharmacist disease management services versus traditional drug regimen review. J Manag Care Pharm 2007;13:28-36.
22. Faragon JJ, Waite NM, Hobson EH, Seoldo N, VanAmburgh JA, Migden H. Improving aspirin prophylaxis in a primary care diabetic population. Pharmacotherapy 2003;23:73-79.
23. Haggerty SA, Cerulli J, Zeolla MM, Cottrell JS, Weck MB, Faragon JJ. Community pharmacy target intervention program to improve aspirin use in persons with diabetes. J Am Pharm Assoc 2005;45:17-22.
24. LaMarr B, Valdez C, Driscoll K, Ryan M. Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. Am J Health Syst Pharm 2010;67:290-294.
25. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med 2005;118:276-284.
26. Simpson SH, Majumdar SR, Tsuyuki RT, Lewanczuk RZ, Spooner R, Johnson JA. Effect of adding pharmacists to primary care teams on blood pressure control in patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2011;34:20-26.
27. Standards of medical care in diabetes, 2007. Diabetes Care 2007;30(suppl 1):S4-S41.
28. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J 1998;316:823-828.
29. Fox CS, Sullivan L, D'Agostino RB Sr, Wilson PW. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. Diabetes Care 2004;27:704-708.
30. Toth EL, Majumdar SR, Guirguis LM, Lewanczuk RZ, Lee TK, Johnson JA. Compliance with clinical practice guidelines for type 2 diabetes in rural patients: treatment gaps and opportunities for improvement. Pharmacotherapy 2003;23:659-665.
31. Majumdar SR, Rowe BH, Folk D, et al. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med 2004;141:366-373.
32. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-3272.